Cell Source, Inc.

CLCS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2016 FY2015 FY2014 FY2013
Operating Activities
Net Income $-967.8K $-2.5M $-4.1M $-1.8M
Depreciation & Amortization — — — —
Depreciation $860 $860 $455 $0
Amortization — — — —
Stock-Based Compensation $114.8K $135.9K $901.3K $0
Net Cash from Operating Activities $-1.5M $-2.0M $-3.1M $894.0K
Investing Activities
Capital Expenditures — — $2.6K $0
Business Acquisitions — — — —
Net Cash from Investing Activities — — — —
Financing Activities
Dividends Paid — — — —
Stock Repurchases — — — —
Net Cash from Financing Activities $1.5M $2.0M — —
Net Change in Cash $-3.2K $-12.5K $-9.4K $-132.4K
Free Cash Flow — — $-3.1M $894.0K
← Newer Page 2 of 2 Older →